Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals

References

• Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al.. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–82.
   PubMed Web of Science ®Google Scholar
• D: A: D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al.. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417–26.
   PubMed Web of Science ®Google Scholar
• D·A·D Study Group. Class of antiretroviral drugs and the risk of myocardial infection. N Engl J Med. 2007;356(17):1723–35.
   PubMed Web of Science ®Google Scholar
• Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, et al.. Lipoprotein particle substances, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207(2):524–9.
   PubMed Web of Science ®Google Scholar
• Currier JS, Havlir DV. Complications of HIV disease and therapy. Top HIV Med. 2008;16(1):23–30.
   PubMedGoogle Scholar
• Baker JV, Neuhaus J, Drupez D, Cooper DA, Hoy J, Kuller L, et al.. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS. 2011;25(17):2133–42.
   PubMed Web of Science ®Google Scholar
• Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, et al.. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10(5):585–91.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, Samore M. Effect of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: a 5-year cohort study. Arch Inern Med. 2000;160:2050–6.
   PubMed Web of Science ®Google Scholar
• Vigano A, Aldrovandi G, Giacomet V, Merlo M, Martelli L, Beretta S, et al.. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10(8):917–24.
   PubMed Web of Science ®Google Scholar
• Townsend ML, Hollowell SB, Bhalodia J, Wilson KH, Kaye KS, Johnson MD. A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS. 2007;18(12):851–5.
   PubMed Web of Science ®Google Scholar
• Panagopoulos P, Tsiodras S, Antoniadou A, Katsarolis I, Papadopoulos A, Poulakou G, et al.. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. Clin Microbiol Infect. 2006;12(5):486–9.
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al.. Guidelines for the evaluation and management of dyslipidemia in Human Immunodeficiency Virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America and the AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–27.
   PubMed Web of Science ®Google Scholar
• Aberg JA. Cardiovascular complications in HIV management: past, present and future. J AIDS. 2009;1(50):54–64.
   Google Scholar
• Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chem. 2004;53:10–4.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrare-Villanneva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al.. One-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral naive HIV-1-infected patients: 96 weeks efficacy and safety results of the CASTLE study. J AIDS. 2010;53:323–32.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Arihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, et al.. Gemini: a non inferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J AIDS. 2009;50:367–74.
   PubMed Web of Science ®Google Scholar
• Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d’Arminio Monforte A, et al.. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056–74.
   PubMed Web of Science ®Google Scholar
• Hill A, Sawyer W, Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz and ritonavir-boosted protease inhibitors on lipids levels. HIV Clin Trials. 2009;10(1):1–12.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al.. AIDS Clinical Trial Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-apring regimens for initial HIV treatment. AIDS. 2009;23(9):1109–18.
   PubMed Web of Science ®Google Scholar
• Perez-Elias MJ, Moreno A, Casado J, Dronda F, Antela A, López D, et al.. Observational study to evaluate clinical outcomes after first-line efavirenz- or lopinavir-ritonavir-based HAART in treatment-naïve patients. J Int Assoc Physicians AIDS Care (Chic). 2009;8(5):308–13.
   PubMedGoogle Scholar
• Domingo P, Suarez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, et al.. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother. 2008;61:1348–58.
   PubMed Web of Science ®Google Scholar
• Dube MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, et al.. Glucose metabolism, lipid and body fat changes in antiretroviral-naïve subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807–18.
   PubMed Web of Science ®Google Scholar
• Shlay JC, Bactoch G, Peng G, Wang J, Grunfeld C, Gibert CL, et al.. Long-term body composition and metabolic changes in antiretroviral naïve persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J AIDS. 2007;44(5):506–17.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, et al.. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007;8(5):280–7.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al.. Class sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–106.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naïve patients. AIDS. 2004;18(17):2331–3.
   PubMed Web of Science ®Google Scholar
• Torti C, Maggiolo F, Patroni A, Suter F, Ladisa N, Paraninfo G, et al.. Exploratory analysis for the evaluation of lopinavir/r-versus efavirenz-based HAART regimens in antiretroviral-naïve HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrib Chemother. 2005;56(1):190–5.
   PubMed Web of Science ®Google Scholar